FDA Grants Orphan Drug Designation to Acucela’s Emixustat Hydrochloride

FDA awarded Acucela an orphan drug designation for its drug candidate emixustat hydrochloride for the treatment of Stargardt disease.

The drug candidate is designed to improve vision by inhibiting an enzyme related to the processing of Vitamin A.